Results · Apr-Jun 2026
Kilitch Drugs (I) Q1 FY27 results
Sales grew 4% to ₹44.9 crore from ₹43.1 crore in Apr-Jun 2025.
Operating profit fell 10% to ₹2.9 crore, an operating margin of 6.5% (down 1.0 points from a year ago).
Net profit fell 13% to ₹2 crore from ₹2.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −50%, net profit −87%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 44.9 | 43.1 | +4% |
| Operating profit (EBITDA) | 2.9 | 3.3 | −10% |
| Operating margin | 6.5% | 7.6% | −1.0 pts |
| Net profit | 2.0 | 2.3 | −13% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.